I Ask This Of You!
I have Parkinson's diseases and thought it would be nice to have a place where the contents of updated news is found in one place. That is why I began this blog.
I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible.
I am not responsible for it's contents. I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish.
This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns.
Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. I will not accept any information about Herbal treatments curing Parkinson's, dementia and etc. It will go into Spam.
This is a free site for all with no advertisements.
Thank you for visiting!
Saturday, January 17, 2015
Thursday, January 15, 2015
medications. One of the more common Parkinson's medications, Levodopa, has
been one of the primary ways of treatment for decades, but the side effects include dyskinesia, a movement disorder characterized by involuntary muscle movements. Moreadith hopes SER-214 will be not only more effective in treatment, but also more effective in limiting some of the drawbacks which come with Levodopa.
Thursday, January 15, 2015Posted: Jan 14, 2015 1:47 PM ESTUpdated: Jan 14, 2015 1:47 PM EST
Wednesday, January 14, 2015
Monday, January 12, 2015
FDA Approves Revolutionary Parkinson's Treatment
and NPF is Helping Deliver It to You
Key Highlights about DUOPA™:
"Due to the progressive nature of Parkinson's disease, it can be difficult to treat over time, especially in the advanced stages," said Joyce Oberdorf, NPF's President and CEO. "Our organization is encouraged by the introduction of a new therapy that may provide another treatment option for affected patients and families."
NPF is collaborating with AbbVie in the development and delivery of comprehensive training programs on DUOPA™ for NPF Centers of Excellence (COEs). NPF considers AbbVie's DUOPA™ product to be an important tool to address unmet clinical needs for advanced Parkinson’s patients. The one-day trainings will be held in the first quarter of 2015 to ensure COEs are among the first sites to be trained. The trainings will include hands-on sessions to provide a strong foundation for key stakeholders involved in managing treatment with DUOPA™.
This news comes on the heels of last week's FDA approval of RYTARY™ (carbidopa and levodopa) extended-release capsules. If you have questions about either of these newly-approved Parkinson's treatments, NPF's Helpline is available at 1-800-4PD-INFO (1-800-473-4636) or firstname.lastname@example.org.
Auspex Pharmaceuticals Announces SD-1077 Program for the Potential Treatment of Parkinson's Disease and Related Movement Disorders
CONTACT: For Media: Dan Budwick, Pure Communications, Inc. email@example.com (973) 271-6085 For Investors: Monique Allaire Lyons, Pure Communications, Inc. firstname.lastname@example.org (617) 895-9511